You just read:

Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

News provided by

Oxford BioDynamics Plc

Nov 08, 2019, 15:00 ET